205 related articles for article (PubMed ID: 11891537)
1. A region close to Tp53 shows LOH in familial breast cancer.
Luo L; Chen J; Du Q; Dumanski J; Blennow E; Kockum I; Luthman H; Lindblom A
Int J Mol Med; 2002 Apr; 9(4):405-9. PubMed ID: 11891537
[TBL] [Abstract][Full Text] [Related]
2. CGH analysis of familial non-BRCA1/BRCA2 breast tumors and mutation screening of a candidate locus on chromosome 17q11.2-12.
Maguire P; Holmberg K; Kost-Alimova M; Imreh S; Skoog L; Lindblom A
Int J Mol Med; 2005 Jul; 16(1):135-41. PubMed ID: 15942690
[TBL] [Abstract][Full Text] [Related]
3. Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations.
Cornelis RS; van Vliet M; Vos CB; Cleton-Jansen AM; van de Vijver MJ; Peterse JL; Khan PM; Børresen AL; Cornelisse CJ; Devilee P
Cancer Res; 1994 Aug; 54(15):4200-6. PubMed ID: 8033152
[TBL] [Abstract][Full Text] [Related]
4. Allelic loss at BRCA1, BRCA2, and adjacent loci in relation to TP53 abnormality in breast cancer.
Tseng SL; Yu IC; Yue CT; Chang SF; Chang TM; Wu CW; Shen CY
Genes Chromosomes Cancer; 1997 Dec; 20(4):377-82. PubMed ID: 9408754
[TBL] [Abstract][Full Text] [Related]
5. Comparative analysis of loss of heterozygosity of specific chromosome 3, 13, 17, and X loci and TP53 mutations in human epithelial ovarian cancer.
Manderson EN; Presneau N; Provencher D; Mes-Masson AM; Tonin PN
Mol Carcinog; 2002 Jun; 34(2):78-90. PubMed ID: 12112314
[TBL] [Abstract][Full Text] [Related]
6. High incidence of loss of heterozygosity at chromosome 17p13 in breast tumours from BRCA2 mutation carriers.
Eiriksdottir G; Barkardottir RB; Agnarsson BA; Johannesdottir G; Olafsdottir K; Egilsson V; Ingvarsson S
Oncogene; 1998 Jan; 16(1):21-6. PubMed ID: 9467939
[TBL] [Abstract][Full Text] [Related]
7. Loss of heterozygosity is detected at chromosomes 1p35-36 (NB), 3p25 (VHL), 16p13 (TSC2/PKD1), and 17p13 (TP53) in microdissected apocrine carcinomas of the breast.
Lininger RA; Zhuang Z; Man Y; Park WS; Emmert-Buck M; Tavassoli FA
Mod Pathol; 1999 Dec; 12(12):1083-9. PubMed ID: 10619258
[TBL] [Abstract][Full Text] [Related]
8. Characterization of familial non-BRCA1/2 breast tumors by loss of heterozygosity and immunophenotyping.
Oldenburg RA; Kroeze-Jansema K; Meijers-Heijboer H; van Asperen CJ; Hoogerbrugge N; van Leeuwen I; Vasen HF; Cleton-Jansen AM; Kraan J; Houwing-Duistermaat JJ; Morreau H; Cornelisse CJ; Devilee P
Clin Cancer Res; 2006 Mar; 12(6):1693-700. PubMed ID: 16551851
[TBL] [Abstract][Full Text] [Related]
9. Detailed deletion mapping in sporadic breast cancer at chromosomal region 17p13 distal to the TP53 gene: association with clinicopathological parameters.
Seitz S; Poppe K; Fischer J; Nothnagel A; Estévez-Schwarz L; Haensch W; Schlag PM; Scherneck S
J Pathol; 2001 Jul; 194(3):318-26. PubMed ID: 11439364
[TBL] [Abstract][Full Text] [Related]
10. Loss of heterozygosity of the putative prostate cancer susceptibility gene HPC2/ELAC2 is uncommon in sporadic and familial prostate cancer.
Wu YQ; Chen H; Rubin MA; Wojno KJ; Cooney KA
Cancer Res; 2001 Dec; 61(24):8651-3. PubMed ID: 11751379
[TBL] [Abstract][Full Text] [Related]
11. Novel somatic mutations in the BRCA1 gene in sporadic breast tumors.
Janatova M; Zikan M; Dundr P; Matous B; Pohlreich P
Hum Mutat; 2005 Mar; 25(3):319. PubMed ID: 15712267
[TBL] [Abstract][Full Text] [Related]
12. BRCA1 and TP53 mutation spectrum of breast carcinoma in an ethnic population of Kashmir, an emerging high-risk area.
Eachkoti R; Hussain I; Afroze D; Aejazaziz S; Jan M; Shah ZA; Das BC; Siddiqi MA
Cancer Lett; 2007 Apr; 248(2):308-20. PubMed ID: 16996204
[TBL] [Abstract][Full Text] [Related]
13. Loss of heterozygosity in human breast carcinomas in the ataxia telangiectasia, Cowden disease and BRCA1 gene regions.
Kerangueven F; Eisinger F; Noguchi T; Allione F; Wargniez V; Eng C; Padberg G; Theillet C; Jacquemier J; Longy M; Sobol H; Birnbaum D
Oncogene; 1997 Jan; 14(3):339-47. PubMed ID: 9018120
[TBL] [Abstract][Full Text] [Related]
14. Loss of heterozygosity at 17p13.3-ter, distal to TP53, correlates with negative hormonal phenotype in sporadic breast cancer.
Roncuzzi L; Brognara I; Baiocchi D; Amadori D; Gasperi-Campani A
Oncol Rep; 2005 Aug; 14(2):471-4. PubMed ID: 16012732
[TBL] [Abstract][Full Text] [Related]
15. BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives.
Lalloo F; Varley J; Moran A; Ellis D; O'dair L; Pharoah P; Antoniou A; Hartley R; Shenton A; Seal S; Bulman B; Howell A; Evans DG
Eur J Cancer; 2006 May; 42(8):1143-50. PubMed ID: 16644204
[TBL] [Abstract][Full Text] [Related]
16. Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity.
Libè R; Groussin L; Tissier F; Elie C; René-Corail F; Fratticci A; Jullian E; Beck-Peccoz P; Bertagna X; Gicquel C; Bertherat J
Clin Cancer Res; 2007 Feb; 13(3):844-50. PubMed ID: 17289876
[TBL] [Abstract][Full Text] [Related]
17. Consortium study on 1280 breast carcinomas: allelic loss on chromosome 17 targets subregions associated with family history and clinical parameters.
Phelan CM; Borg A; Cuny M; Crichton DN; Baldersson T; Andersen TI; Caligo MA; Lidereau R; Lindblom A; Seitz S; Kelsell D; Hamann U; Rio P; Thorlacius S; Papp J; Olah E; Ponder B; Bignon YJ; Scherneck S; Barkardottir R; Borresen-Dale AL; Eyfjörd J; Theillet C; Thompson AM; Larsson C
Cancer Res; 1998 Mar; 58(5):1004-12. PubMed ID: 9500463
[TBL] [Abstract][Full Text] [Related]
18. Sporadic breast carcinomas with somatic BRCA1 gene deletions share genotype/phenotype features with familial breast carcinomas.
Rhiem K; Todt U; Wappenschmidt B; Klein A; Wardelmann E; Schmutzler RK
Anticancer Res; 2010 Sep; 30(9):3445-9. PubMed ID: 20944121
[TBL] [Abstract][Full Text] [Related]
19. Loss of heterozygosity in familial breast carcinomas.
Lindblom A; Skoog L; Rotstein S; Werelius B; Larsson C; Nordenskjöld M
Cancer Res; 1993 Sep; 53(18):4356-61. PubMed ID: 8364930
[TBL] [Abstract][Full Text] [Related]
20. Multiple target sites of allelic imbalance on chromosome 17 in Barrett's oesophageal cancer.
Dunn J; Garde J; Dolan K; Gosney JR; Sutton R; Meltzer SJ; Field JK
Oncogene; 1999 Jan; 18(4):987-93. PubMed ID: 10023674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
